Skin specialist biopharma firm Dermira has seen its stock crash and burn following the announcement that it plans to terminate development of acne treatment olumacostat glasaretil after it failed to show statistically significant efficacy as a therapy for moderate to severe forms of the skin condition in patients older than nine years old.
Ook interessant voor je
Reageer